Differential requirements of PI3K subunits for BCR or BCR/CD19-induced ERK activation

Advances in Experimental Medicine and Biology

Volumn 584, Issue , 2006, Pages 43-52

  Vigorito, Elena ^a   Turner, Martin ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934436349     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34132-3_4     Document Type: Conference Paper

References (43)

1. J. A. Deane and D. A. Fruman, Phosphoinositide 3-kinase: diverse roles in immune cell activation, Annu Rev Immunol 22, 563-598 (2004).
2. B. Vanhaesebroeck, S. J. Leevers, K. Ahmadi, J. Timms, R. Katso, P. C. Driscoll, R. Woscholski, P. J. Parker and M. D. Waterfield, Synthesis and function of 3-phosphory-lated inositol lipids, Annu Rev Biochem 70, 535-602 (2001).
3. D. Chantry, A. Vojtek, A. Kashishian, D. A. Holtzman, C. Wood, P. W. Gray, J. A. Cooper and M. F. Hoekstra, P110δ, a novel phospahatidylinositol 3-kinase catalytic subunit that assocites with p85 and is expressed predominantly in leukocytes, J. Biol. Chem. 272, 19236-19241 (1997).
4. I. D. Hiles, M. Otsu, S. Volinia, M. J. Fry, I. Gout, R. Dhand, G. Panayotou, F. Ruiz-Larrea, A. Thompson, N. F. Totty and et al., Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit, Cell 70 (3), 419-429 (1992).
5. P. Hu, A. Mondino, E. Y. Skolnik and J. Schlessinger, Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85, Mol Cell Biol 13 (12), 7677-7688 (1993).
6. K. Inukai, M. Anai, E. Van Breda, T. Hosaka, H. Katagiri, M. Funaki, Y. Fukushima, T. Ogihara, Y. Yazaki, Kikuchi, Y. Oka and T. Asano, A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene, J Biol Chem 271, (10), 5317-5320 (1996).
7. D. A. Antonetti, P. Algenstaedt and C. R. Kahn, Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain, Mol Cell Biol 16 (5), 2195-2203 (1996).
8. K. Inukai, M. Funaki, T. Ogihara, H. Katagiri, A. Kanda, M. Anai, Y. Fukushima, T. Hosaka, M. Suzuki, B. C. Shin, K. Takata, Y. Yazaki, M. Kikuchi, Y. Oka and T. Asano, p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin, J Biol Chem 272 (12), 7873-7882 (1997).
9. D. A. Fruman, L. C. Cantley and C. L. Carpenter, Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene, Genomics 37 (1), 113-121 (1996).
10. N. Engels, B. Wollscheid and J. Weinlands, Association of SLP65/BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-α, Eur. J. Immunol. 31, 2126-2134 (2001).
11. A. L. DeFranco, Vav and the B cell signalosome, Nat. Immunol. 2, 482-484 (2001).
12. C. W. Chiu, M. Dalton, M. Ishiai, T. Kurosaki and A. C. Chan, BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins, EMBO J. 21 (23), 6461-6472 (2002).
13. H. Niiro and E. A. Clark, Regulation of B-cell fate by antigen-receptor signals, Nat. Rev. Immunol. 2 (12), 945-956 (2002).
14. C. Dong, R. J. Davis and R. A. Flavell, MAP kinases in the immune response, Annu Rev Immunol 20, 55-72 (2002).
15. T. Kurosaki, Genetic analysis of B cell antigen receptor signaling, Annu. Rev. Immunol. 17 555-592 (1999).
16. T. G. Boulton, G. D. Yancopoulos, J. S. Gregory, C. Slaughter, C. Moomaw, J. Hsu and M. H. Cobb, An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control, Science 249 (4964), 64-67 (1990).
17. T. G. Boulton, S. H. Nye, D. J. Robbins, N. Y. Ip, E. Radziejewska, S. D. Morgenbesser, R. A. DePinho, N. Panayotatos, M. H. Cobb and G. D. Yancopoulos, ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF, Cell 65 (4), 663-675 (1991).
18. T. Nekrasova, C. Shive, Y. Gao, K. Kawamura, R. Guardia, G. Landreth and T. G. Forsthuber, ERK1-Deficient Mice Show Normal T Cell Effector Function and Are Highly Susceptible to Experimental Autoimmune Encephalomyelitis, J Immunol 175 (4), 2374-2380 (2005).
19. N. Hatano, Y. Mori, M. Oh-hora, A. Kosugi, T. Fujikawa, N. Nakai, H. Niwa, J. Miyazaki, T. Hamaoka and M. Ogata, Essential role for ERK2 mitogen-activated protein kinase in placental development, Genes Cells 8 (11), 847-856 (2003).
20. M. K. Saba-El-Leil, F. D. Vella, B. Vernay, L. Voisin, L. Chen, N. Labrecque, S. L. Ang and S. Meloche, An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development, EMBO Rep 4 (10), 964-968 (2003).
21. D. A. Fruman, S. B. Snapper, C. M. Yballe, L. Davidson, J. Y. Yu, F. W. Alt and L. C. Cantley, Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha, Science 283 (5400), 393-397 (1999).
22. H. Suzuki, Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki, T. Kadowaki and S. Koyasu, Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase, Science 283 (5400), 390-392 (1999).
23. D. Fruman, A. B. Satterthwaite and O. N. Witte, Xid-like Phenotypes: A B cell signalosome takes shape, Immunity 13, 1-3 (2000).
24. A. C. Donahue, K. L. Hess, K. L. Ng and D. A. Fruman, Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha, Int Immunol 16 (12), 1789-1798 (2004).
25. J. A. Deane, M. J. Trifilo, C. M. Yballe, S. Choi, T. E. Lane and D. A. Fruman, Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase, J Immunol 172 (11), 6615-6625 (2004).
26. L. Bi, I. Okabe, D. J. Bernard, A. Wynshaw-Boris and R. Nussbaum, Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase, J. Biol. Chem. 274, 10963-10968 (1999).
27. L. Bi, I. Okabe, D. J. Bernard and R. L. Nussbaum, Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase, Mamm Genome 13 (3), 169-172 (2002).
28. E. Clayton, G. Bardi, S. E. Bell, D. Chantry, C. P. Downes, A. Gray, L. A. Humphries, D. Rawlings, H. Reynolds, E. Vigorito and M. Turner, A crucial role for the p110 delta subunit of phosphatidylinositol 3-kinase in B cell development and activation, J. Exp. Med. 196 (6), 753-763 (2002).
29. K. Okkenhaug, A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S. E. Meek, A. Salpekar, M. D. Waterfield, A. J. H. Smith and B. Vanhaesebroeck, Impaired B and T cell antigen receptor signaling in p110 delta PI 3-kinase mutant mice, Science 297 (5583), 1031-1034 (2002).
30. S. T. Jou, N. Carpino, Y. Takahashi, R. Piekorz, J. R. Chao, D. M. Wang and J. N. Ihle, Essential, nonredundant role for the phosphoinositide 3-kinase p110 delta in signaling by the B-cell receptor complex, Mol. Cell. Biol. 22 (24), 8580-8591 (2002).
31. K. Okkenhaug and B. Vanhaesebroeck, PI3K in lymphocyte development, differentiation and activation, Nat. Rev. Immunol. 3 (4), 317-330 (2003).
32. K. L. Hess, A. C. Donahue, K. L. Ng, T. I. Moore, J. Oak and D. A. Fruman, Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses, Eur J Immunol 34 (11), 2968-2976 (2004).
33. E. Vigorito, G. Bardi, J. Glassford, E. W. Lam, E. Clayton and M. Turner, Vavdependent and vav-independent phosphatidylinositol 3-kinase activation in murine B cells determined by the nature of the stimulus, J Immunol 173 (5), 3209-3214 (2004).
34. A. Jacob, D. Cooney, M. Pradhan and K. M. Coggeshall, Convergence of signaling pathways on the activation of ERK in B cells, J. Biol. Chem. 277 (26), 23420-23426 (2002).
35. Y. Aiba, M. Oh-hora, S. Kiyonaka, Y. Kimura, A. Hijikata, Y. Mori and T. Kurosaki, Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptormediated Ras activation, Proc Natl Acad Sci U S A 101 (47), 16612-16617 (2004).
36. D. T. Fearon and M. C. Carroll, Regulation of B Lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex., Annu. Rev. Immunol. 18, 393-422 (2000).
37. D. A. Tuveson, R. H. Carter, S. P. Soltoff and D. T. Fearon, CD19 of B cells as a surrogate kinase insert region to bind phospahtidylinositol 3-kinase, Science 260, 986-989 (1993).
38. Y. Wang, S. R. Brooks, X. L. Li, A. N. Anzelon, R. C. Rickert and R. H. Carter, The physiologic role of CD19 cytoplasmic tyrosines, Immunity 17 (4), 501-514 (2002).
39. A. M. Buhl, C. M. Pleiman, R. R. Rickert and J. C. Cambier, Qualititive Regulation of B Cell Antigen Receptor Signalling by CD19: Selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization., J. Exp. Med. 186, 1897-1910 (1998).
40. T. O. Chan, S. E. Rittenhouse and P. N. Tsichlis, AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation, Annu Rev Biochem 68, 965-1014 (1999).
41. L. O'Rourke, R. Tooze, M. Turner, D. M. Sandoval, R. H. Carter, V. L. J. Tybulewicz and D. T. Fearon, CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav, Immunity 8, 635-645 (1998).
42. R. M. Tooze, G. M. Doody and D. T. Fearon, Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin, Immunity 7 (1), 59-67 (1997).
43. X. Li and R. H. Carter, Convergence of CD19 and B cell antigen receptor signals at MEK1 in the ERK2 activation cascade, J Immunol 161 (11), 5901-5908 (1998).